This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bloechl-Daum, B. Articles by Herrstedt, J. Search for Related Content PubMed PubMed Citation Articles by Bloechl-Daum, B. Articles by Herrstedt, J. Social Bookmarking                            What's this?

Delayed Nausea and Vomiting Continue to Reduce Patients' Quality of Life After Highly and Moderately Emetogenic Chemotherapy Despite Antiemetic Treatment

Brigitte Bloechl-Daum, Robert R. Deuson, Panagiotis Mavros, Mogens Hansen, Jørn Herrstedt

From the Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria; Outcomes Research, Merck & Co, Whitehouse Station, NJ; Department of Internal Medicine F, Hillerød Hospital, Hillerød; and the Department of Oncology, Copenhagen University Hospital Herlev, Herlev, Denmark

Address reprint requests to Brigitte Bloechl-Daum, MD, Department of Clinical Pharmacology, Medical University of Vienna, Allgemeines Krankenhaus, Waehringer Guertel 18-20, A-1090 Vienna, Austria; e-mail: brigitte.bloechl-daum{at}meduniwien.ac.at

PURPOSE: Chemotherapy-induced nausea and vomiting (CINV) are major adverse effects of cancer chemotherapy. We compared the impact of acute (during the first 24 hours postchemotherapy) and delayed (days 2 through 5 postchemotherapy) CINV on patients' quality of life (QoL) after highly or moderately emetogenic chemotherapy (HEC and MEC, respectively).

PATIENTS AND METHODS: This prospective, multicenter, multinational study was conducted in 14 medical practices on cancer patients undergoing either HEC or MEC treatment. Patients recorded episodes of nausea and vomiting in a diary. Patients completed the Functional Living Index-Emesis (FLIE) questionnaire at baseline and on day 6.

RESULTS: A total of 298 patients were assessable (67 HEC patients, 231 MEC patients). Emesis was reported by 36.4% of patients (13.2% acute, 32.5% delayed) and nausea by 59.7% (36.2% acute, 54.3% delayed). HEC patients reported significantly lower mean FLIE total score than MEC patients (95.5 v 107.8 respectively; P = .0049). Among all patients, the nausea score was significantly lower than the vomiting score (50.0 and 55.3, respectively; P = .0097). Of the 173 patients who experienced neither vomiting nor nausea during the first 24 hours postchemotherapy, 22.9% reported an impact of CINV on daily life caused by delayed CINV.

CONCLUSION: CINV continues to adversely affect patients' QoL despite antiemetic therapy even after treatment with only moderately emetogenic chemotherapy regimens, and even in the subgroup of patients who do not experience nausea and vomiting during the first 24 hours. On the basis of the FLIE results in this study, nausea had a stronger negative impact on patients' daily lives than vomiting.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Maemondo, N. Masuda, I. Sekine, K. Kubota, Y. Segawa, M. Shibuya, F. Imamura, N. Katakami, T. Hida, S. Takeo, et al. A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy Ann. Onc., June 26, 2009; (2009) mdp195v1. [Abstract] [Full Text] [PDF]

				V. Shih, H. S. Wan, and A. Chan Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide Ann. Pharmacother., March 1, 2009; 43(3): 444 - 452. [Abstract] [Full Text] [PDF]

				P. H. Pan, S. C. Lee, and L. C. Harris Antiemetic Prophylaxis for Postdischarge Nausea and Vomiting and Impact on Functional Quality of Living During Recovery in Patients with High Emetic Risks: A Prospective, Randomized, Double-Blind Comparison of Two Prophylactic Antiemetic Regimens Anesth. Analg., August 1, 2008; 107(2): 429 - 438. [Abstract] [Full Text] [PDF]

				P. J. Hesketh Chemotherapy-Induced Nausea and Vomiting N. Engl. J. Med., June 5, 2008; 358(23): 2482 - 2494. [Full Text] [PDF]

				A. Chan, V. Shih, and L. Chew Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre{dagger} Journal of Oncology Pharmacy Practice, March 1, 2008; 14(1): 23 - 29. [Abstract] [PDF]